vertex - International Biopharmaceutical Industry

news

Vertex adds to Boston expansion with plans for new site

Dive Brief: Fresh off the dedication of a major new building in Boston’s Seaport, Vertex Pharmaceuticals said it’s making plans for yet another facility that it cl...

22 May 2022 news Biotech | Boston

Continue Reading →

news

Vertex gets positive trial results for non-opioid painkiller in boost to pipeline

Dive Brief: Vertex plans to advance an experimental drug it's developing for acute pain into late-stage testing later this year after reporting positive results fr...

1 April 2022 news boost | painkiller

Continue Reading →

news

Vertex plans path to FDA for top drug prospect

Dive Brief: Vertex will begin late-stage testing of one of its top drug prospects later this month, announcing on Tuesday plans for a Phase 2/3 clinical trial that...

25 March 2022 news Drug | FDA

Continue Reading →

news

Amgen partners with Arrakis to develop drugs aimed at RNA

Dive Brief: Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, Massa...

14 January 2022 news AstraZeneca | Drugs

Continue Reading →

news

Boehringer Ingelheim takes next step in development of cystic fibrosis gene therapy

Boston biotech Vertex is the leading developer of cystic fibrosis medicines. Its four approved drugs can treat most patients. Trikafta, the one most recently approved...

22 October 2021 news Boehringer Ingelheim | cystic fibrosis

Continue Reading →

news

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Vertex is best known for its work in cystic fibrosis, having developed four approved medicines that, by the company's estimates, can treat about 90% of the patient po...

27 August 2021 news Biotech | cystic fibrosis

Continue Reading →

news

Vertex, CRISPR gene-editing therapy hit with clinical hold

U.S. regulators have placed a clinical hold on CRISPR Therapeutics' lead candidate, spurring a double-digit drop in the Swiss biotech's stock value by Thursday mo...

1 June 2018 news clinical | CRISPR

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Vertex adds to Boston expansion with plans for new site

Vertex gets positive trial results for non-opioid painkiller in boost to pipeline

Vertex plans path to FDA for top drug prospect

Amgen partners with Arrakis to develop drugs aimed at RNA

Boehringer Ingelheim takes next step in development of cystic fibrosis gene therapy

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Vertex, CRISPR gene-editing therapy hit with clinical hold

International Biopharmaceutical Industry